

**19 October 2023**

**Oncimmune Holdings plc**

("Oncimmune" or the "Company")

**Investor Presentation via Investor Meet Company**

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, is pleased to announce that Martin Gouldstone, Chief Executive Officer, and Martin Hudson, Finance Director, will provide a live presentation relating to the Company's updated strategy, as announced on 12 October 2023, via Investor Meet Company on 25 October 2023 at 12.00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Oncimmune Holdings plc via:

<https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor>

Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited.

**For further information:**

[contact@oncimmune.co.uk](mailto:contact@oncimmune.co.uk)

**Singer Capital Markets (Nominated Adviser and Broker)**

Phil Davies, Harry Gooden, James Fischer  
+44 (0)20 7496 3000

**Zeus (Joint Broker)**

Dominic King, Victoria Ayton, Dan Bate  
+44 (0)20 3829 5000  
+44 (0)20 3727 1000

**About Oncimmune**

Oncimmune is a global leader in immune biomarkers and immunodiagnostics, offering autoantibody biomarker profiling in immunooncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the Company provides insights and analytics to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit [www.oncimmune.com](http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBSBDGGXBDGXI